

ASX Announcement

Danny Sharp appointed an Independent Non-Executive Director of Race

- Former Executive Director of Canaccord Genuity, Danny Sharp brings a deep understanding of capital markets with an extensive network of institutional and private wealth investors
- More than 25 years of global institutional investment banking experience focused in the healthcare and technology sectors
- Appointment adds an additional independent director to the Race Board, further building Race's financial and governance expertise.

5 December 2022 – Race Oncology Limited ("Race") is pleased to announce that Mr Daniel (Danny) Sharp has been appointed as an Independent Non-Executive Director.

After commencing his career as a solicitor, Mr Sharp has had an extensive investment banking career of more than 25 years where he has advised the boards of technology and healthcare-based organisations on global capital markets. He has an extensive network of institutional and private wealth investors.

From 2012 to 2020, Mr Sharp was an Executive Director of leading independent, financial services firm Canaccord Genuity. He is currently a Non-Executive Director of health informatics company, Alcidion Group Limited (ASX: ALC) and Non-Executive Director of the dermatology-focused Botanix Pharmaceuticals Limited (ASX: BOT). He is also a member of the investment committee of the Baker Heart and Diabetes Institute Foundation.

Mr Sharp previously headed the corporate banking division of Shaw and Partners and Lodge Partners. He holds a Bachelor of Economics and Law and is a CFA Charter Holder.

Chair, Dr John Cullity said: *"On behalf of my fellow directors, I am delighted to welcome Danny Sharp to the Board of Race. His appointment aligns with our focus on preparing the Company for substantial engagement with commercial partners and institutional investors as we take forward our Three Pillar strategy. It also broadens our independent director pool and brings additional legal, financial and governance experience to the Board."*

Subject to shareholder approval, Mr Sharp will be issued 110,392 options to acquire shares in the Capital of the Company at an exercise price of \$3.32 each and expiring 5 years from the date of issue. One third of the options will vest 12 months from the date of issue and the remaining two thirds of the options will vest monthly over the following 24 months, provided that Mr Sharp remains as a Director of the Company during the vesting period.



In addition, it is proposed, subject to shareholder approval to issue 110,392 options to Ms Mary Harney on the same terms and conditions as outlined above.

-ENDS-

About Race Oncology (ASX: RAC)

Race Oncology is an ASX listed precision oncology company with a Phase 2/3 cancer drug called Zantrene®.

Zantrene is a potent inhibitor of the Fatso/Fat mass and obesity associated (FTO) protein. Overexpression of FTO has been shown to be the genetic driver of a diverse range of cancers. Race is exploring the use of Zantrene as a new therapy for melanoma and clear cell renal cell carcinoma, which are both frequent FTO over-expressing cancers.

In breakthrough preclinical research, Race has also discovered that Zantrene protects from anthracycline-induced heart damage, while in tandem acting with anthracyclines and proteasome inhibitors to improve their ability to target cancer.

The Company also has compelling clinical data for Zantrene as a chemotherapeutic agent and is in clinical trial in Acute Myeloid Leukaemia (AML).

Race is pursuing outsized commercial returns for shareholders via its 'Three Pillar' strategy.

Learn more at www.raceoncology.com

Race encourages all investors to go paperless by registering their details with the Company's share registry, Automic Registry Services, at www.automicgroup.com.au

Release authorised by:

Phil Lynch, CEO/MD on behalf
of the Race Board of Directors
phillip.lynch@raceoncology.com

Media contact:

Jane Lowe
+61 411 117 774
jane.lowe@irdepartment.com.au